Last reviewed 2026-05-30 · How we verify

Skin test panel and desensitization kit

EVE Medical Systems Ltd. · Phase 2 active Small molecule ✓ Verified May 2026

Skin test panel and desensitization kit is a Small molecule drug developed by EVE Medical Systems Ltd.. It is currently in Phase 2 development. Also known as: Progesterone, Estradiol, Estrone, Estriol.

A skin test panel and desensitization kit has been studied as a potential treatment for Premenstrual Syndrome in a clinical trial. The skin test panel is used to diagnose and the desensitization kit is used to treat, but the exact mechanism of action is unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Skin test panel and desensitization kit
Also known as	Progesterone, Estradiol, Estrone, Estriol
Sponsor	EVE Medical Systems Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Skin test panel and desensitization kit CI brief — competitive landscape report
Skin test panel and desensitization kit updates RSS · CI watch RSS
EVE Medical Systems Ltd. portfolio CI

Frequently asked questions about Skin test panel and desensitization kit

What is Skin test panel and desensitization kit?

Skin test panel and desensitization kit is a Small molecule drug developed by EVE Medical Systems Ltd..

Who makes Skin test panel and desensitization kit?

Skin test panel and desensitization kit is developed by EVE Medical Systems Ltd. (see full EVE Medical Systems Ltd. pipeline at /company/eve-medical-systems-ltd).

Is Skin test panel and desensitization kit also known as anything else?

Skin test panel and desensitization kit is also known as Progesterone, Estradiol, Estrone, Estriol.

What development phase is Skin test panel and desensitization kit in?

Skin test panel and desensitization kit is in Phase 2.

Manufacturer: EVE Medical Systems Ltd. — full pipeline
Also known as: Progesterone, Estradiol, Estrone, Estriol

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing